Stock Information
symbol line chart

PBSVPharma-Bio Serv Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

N/A

Location

N/A, Puerto Rico

Exchange

OTC

Website

https://www.pharmabioserv.com

Summary

Pharma-Bio Serv, Inc.

Company Info

CEO

N/A

Location

N/A, Puerto Rico

Exchange

OTC

Website

https://www.pharmabioserv.com

Summary

Pharma-Bio Serv, Inc.

AI Insights for PBSV
5 min read

Quick Summary

Pharma-Bio Serv, Inc. is a Puerto Rico-based consulting company that serves regulated industries, especially pharmaceutical, biotechnology, medical device, chemical, cosmetic, food, beverage, and allied products companies. The company provides compliance, regulatory, quality, validation, engineering, and technical consulting services rather than selling a physical consumer product. Its customers are typically manufacturers and operators that must comply with FDA, GMP, quality-system, validation, and other regulatory requirements. The company’s value proposition is helping clients prepare for inspections, validate processes and facilities, maintain quality systems, and meet regulatory expectations. Pharma-Bio Serv is a very small OTC-traded public company, with a market capitalization of roughly $10.3 million based on the provided data, so customer concentration and contract timing can materially affect its reported results.

Strengths

•

Pharma-Bio Serv’s primary strength is its specialization in compliance, quality, validation, and regulatory consulting for highly regulated industries.

•

The company has been operating since 1993, which gives it a long history in a niche market where experience and credibility matter.

•

Its customer base is tied to life sciences and regulated manufacturing, areas where compliance is not optional and where external expertise is often needed.

•

The provided valuation metrics suggest the market may be assigning a relatively low enterprise value to revenue and EBITDA, which can be attractive if the company stabilizes profitability.

•

The company also appears to have a small but established workforce of 185 employees, giving it operating capacity while still remaining flexible compared with larger competitors.

Key Risks

•

The key risks for Pharma-Bio Serv include customer concentration, project timing volatility, margin pressure, and competition from larger consulting firms.

•

If major clients delay projects, reduce compliance spending, or bring more work in-house, the company’s revenue and profitability could decline quickly.

•

The consulting business depends heavily on attracting and retaining qualified professionals, so employee turnover or wage inflation could hurt service quality and margins.

•

OTC microcap stocks also carry significant market risks, including low liquidity, wider bid-ask spreads, limited analyst coverage, and susceptibility to speculative trading.

What to Watch

During the most recent reported quarter, Pharma-Bio Serv’s fundamentals showed modest revenue generation but weak profitability.
The company reported total revenue and operating revenue of approximately $2.34 million, gross profit of approximately $691,734, operating income of negative $71,812, and net income of negative $14,219.
Diluted EPS was reported at approximately negative $0.001, indicating that profitability remained thin or slightly negative during the period.
There was no provided evidence of a major new product launch, acquisition, dividend increase, or strategic partnership by Pharma-Bio Serv during the quarter.
The most notable external development was industry consolidation in the life sciences validation and compliance market, including Pinnaql’s acquisition of Validation & Engineering Group, which may affect competitive dynamics for firms like Pharma-Bio Serv.

Price Drivers

•

PBSV’s stock price is likely driven by microcap and OTC-market dynamics as much as by company fundamentals.

•

The provided data show a small market capitalization of about $10.3 million, low recent trading volume, and a 52-week range of $0.32 to $0.61, all of which suggest that relatively small trades or news items can move the share price materially.

•

Earnings and revenue trends are important drivers because the company reported roughly $2.34 million of operating revenue, negative operating income, and a small net loss in the most recent data set.

•

Valuation metrics such as price-to-book value near 0.99, EV-to-revenue near 0.18, and EV-to-EBITDA near 4.34 may attract value-oriented investors, but the negative diluted EPS and limited liquidity may offset that appeal.

•

Broader interest in speculative penny stocks, demand for life sciences compliance services, industry consolidation, and investor caution about OTC securities can all influence sentiment and price movement.

Recent News

•

Recent news included Pharma-Bio Serv being mentioned in an article about speculative penny stocks trading under $1.

•

The article described PBSV as a Puerto Rico-based provider of regulatory, compliance, and quality services for life sciences, food, beverage, and consumer-products companies.

•

It highlighted the company’s strong balance sheet, high cash-to-debt profile, and discounted earnings valuation as potential positives for risk-tolerant investors.

•

The article also warned that penny stocks can be extremely volatile and may be vulnerable to sharp losses, scams, or manipulation.

•

Separately, industry news reported Pinnaql’s acquisition of Validation & Engineering Group, which is not a Pharma-Bio Serv transaction but is relevant because it shows consolidation in the validation, quality, compliance, and regulatory consulting market.

Market Trends

•

The broader market for Pharma-Bio Serv’s services is shaped by continued regulatory oversight of pharmaceutical, biotechnology, medical-device, food, beverage, and consumer-product manufacturing.

•

Demand for validation, quality assurance, regulatory consulting, and compliance remediation remains important because companies must maintain inspection readiness and product-quality standards.

•

A major trend is consolidation among life sciences service providers, as private-equity-backed platforms seek to build larger end-to-end compliance and validation businesses.

•

Another trend is the increased use of digital quality systems, computerized validation tools, and data-integrity controls, which may shift client demand toward technology-enabled consulting.

•

At the stock-market level, microcap OTC names like PBSV are affected by low liquidity, speculative trading cycles, investor risk appetite, and sensitivity to small changes in financial performance.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on PBSV

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show